Pharmacogenomics and the Treatment of Acute Myeloid Leukemia

References

• Löwenberg B . Acute myeloid leukemia: the challenge of capturing disease variety . Hematology Am. Soc. Hematol. Educ. Program.2008 , 1 – 11 ( 2008 ).
   Google Scholar
• International Transporter Consortium , GiacominiKM , HuangSMet al.Membrane transporters in drug development . Nat. Rev. Drug Discov.9 , 215 – 236 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Lal S , MahajanA , ChenWN , ChowbayB . Pharmacogenetics of target genes across doxorubicin disposition pathway: a review . Curr. Drug Metab.11 , 115 – 128 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Seedhouse CH , GrundyM , WhitePet al. Sequential influences of leukemia-specific and genetic factors on P-glycoprotein expression in blasts from 817 patients entered into the National Cancer Research Network acute myeloid leukemia 14 and 15 trials . Clin. Cancer Res.13 , 7059 – 7066 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Lamba J , StromS , VenkataramananRet al. MDR1 genotype is associated with hepatic cytochrome P4503A4 basal and induction phenotype . Clin. Pharmacol. Ther.79 , 325 – 338 ( 2006 ).
   PubMed Web of Science ®Google Scholar
• Kurata Y , IeiriI , KimuraMet al. Role of human MDR1 gene polymorphism in bioavailability and interaction of digoxin, a substrate of P-glycoprotein . Clin. Pharmacol. Ther.72 , 209 – 219 ( 2002 ).
   PubMed Web of Science ®Google Scholar
• Illmer T , SchulerUS , ThiedeCet al. MDR1 gene polymorphisms affect therapy outcome in acute myeloid leukemia patients . Cancer Res.62 , 4955 – 4962 ( 2002 ).
   PubMed Web of Science ®Google Scholar
• Kim DH , ParkJY , SohnSKet al. Multidrug resistance-1 gene polymorphisms associated with treatment outcomes in de novo acute myeloid leukemia . Int. J. Cancer118 , 2195 – 2201 ( 2006 ).
   PubMed Web of Science ®Google Scholar
• van der Holt B , Van den Heuvel-EibrinkMM , Van SchaikRHet al. ABCB1 gene polymorphisms are not associated with treatment outcome in elderly acute myeloid leukemia patients . Clin. Pharmacol. Ther.80 , 427 – 439 ( 2006 ).
   PubMed Web of Science ®Google Scholar
• Monzo M , BrunetS , Urbano-IspizuaAet al. CETLAM. Genomic polymorphisms provide prognostic information in intermediate-risk acute myeloblastic leukemia . Blood107 , 4871 – 4879 ( 2006 ).
   PubMed Web of Science ®Google Scholar
• Kim YK , KimHN , LeeIKet al. Prognostic significance of ABCB1 (MDR1) gene polymorphisms in de novo acute myeloid leukemia with t(8;21) or inv(16) . Blood (ASH Annual Meeting Abstracts)110 , Abstract 4271 ( 2007 ).
   Google Scholar
• Hur EH , LeeJH , LeeMJet al. C3435T polymorphism of the MDR1 gene is not associated with P-glycoprotein function of leukemic blasts and clinical outcome in patients with acute myeloid leukemia . Leuk. Res.32 , 1601 – 1604 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Hampras SS , SuchestonL , WeissJet al. Genetic polymorphisms of ATP-binding cassette (ABC) proteins, overall survival and drug toxicity in patients with acute myeloid leukemia . Int. J. Mol. Epidemiol. Genet.1 , 201 – 207 ( 2010 ).
   PubMedGoogle Scholar
• Kim YK , BaeSY , KimHNet al. Prognostic impact of DNA repair and MDR-1 gene polymorphisms in de novo acute myeloid leukemia with t(8;21) or Inv(16) . Blood (ASH Annual Meeting Abstracts)116 , Abstract 1714 ( 2010 ).
   Google Scholar
• Gréen H , FalkIJ , LotfiKet al. Association of ABCB1 polymorphisms with survival and in vitro cytotoxicty in de novo acute myeloid leukemia with normal karyotype . Pharmacogenomics J.12 , 111 – 118 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Scheiner MA , da Cunha VasconcelosF , da MattaRR , Dal Bello FigueiraRJr , MaiaRC . ABCB1 genetic variation and P-glycoprotein expression/activity in a cohort of Brazilian acute myeloid leukemia patients . J. Cancer Res. Clin. Oncol.138 , 959 – 969 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Jakobsen Falk I , FyrbergA , PaulEet al. Impact of ABCB1 single nucleotide polymorphisms 1236C>T and 2677G>T on overall survival in FLT3 wild-type de novo AML patients with normal karyotype . Br. J. Haematol.167 , 671 – 680 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• He H , YinJY , XuYJet al. Association of ABCB1 polymorphisms with the efficacy of ondansetron in chemotherapy-induced nausea and vomiting . Clin. Ther.36 , 1242.e2 – 1252.e2 ( 2014 ).
   Web of Science ®Google Scholar
• He H , YinJ , LiXet al. Association of ABCB1 polymorphisms with prognostic outcomes of anthracycline and cytarabine in Chinese patients with acute myeloid leukemia . Eur. J. Clin. Pharmacol.71 , 293 – 302 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Megías-Vericat JE , RojasL , HerreroMJet al. Influence of ABCB1 polymorphisms upon the effectiveness of standard treatment for acute myeloid leukemia: a systematic review and meta-analysis of observational studies . Pharmacogenomics J.15 , 109 – 118 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Megías JE , MontesinosP , HerreroMJet al. Impact of transporter genes polymorphisms in standard induction of acute myeloid leukemia . Blood (ASH Annual Meeting Abstracts)126 , 4842 ( 2015 ).
   Web of Science ®Google Scholar
• Visscher H , RossCJ , RassekhSRet al. Pharmacogenomic prediction of anthracycline-induced cardiotoxicity in children . J. Clin. Oncol.30 , 1422 – 1428 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Wojnowski L , KulleB , SchirmerMet al. NAD(P)H oxidase and multidrug resistance protein genetic polymorphisms are associated with doxorubicin-induced cardiotoxicity . Circulation112 , 3754 – 3762 ( 2005 ).
   PubMed Web of Science ®Google Scholar
• Yee SW , MeffordJA , SinghNet al. Impact of polymorphisms in drug pathway genes on disease-free survival in adults with acute myeloid leukemia . J. Hum. Genet.58 , 353 – 361 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Müller P , AsherN , HeledM , CohenSB , RischA , RundD . Polymorphisms in transporter and Phase II metabolism genes as potential modifiers of the predisposition to and treatment outcome of de novo acute myeloid leukemia in Israeli ethnic groups . Leuk. Res.32 , 919 – 929 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Drenberg CD , PaughSW , PoundsSBet al. Inherited variation in OATP1B1 is associated with treatment outcome in acute myeloid leukemia . Clin. Pharmacol. Ther.99 ( 6 ), 651 – 660 ( 2015 ).
   Web of Science ®Google Scholar
• Niemi M , PasanenMK , NeuvonenPJ . Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake . Pharmacol. Rev.63 , 157 – 181 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Iacobucci I , LonettiA , CandoniAet al. Profiling of drug-metabolizing enzymes/transporters in CD33+ acute myeloid leukemia patients treated with gemtuzumab–ozogamicin and fludarabine, cytarabine and idarubicin . Pharmacogenomics J.13 , 335 – 341 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Lal S , WongZW , JadaSRet al. Novel SLC22A16 polymorphisms and influence on doxorubicin pharmacokinetics in Asian breast cancer patients . Pharmacogenomics8 , 567 – 575 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Bray J , SluddenJ , GriffinMJet al. Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide . Br. J. Cancer102 , 1003 – 1009 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Lal S , MahajanA , ChenWN , ChowbayB . Pharmacogenetics of target genes across doxorubicin disposition pathway: a review . Curr. Drug Metab.11 , 115 – 128 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Blanco JG , LeisenringWM , Gonzalez-CovarrubiasVMet al. Genetic polymorphisms in the carbonyl reductase 3 gene CBR3 and the NAD(P)H:quinone oxidoreductase 1 gene NQO1 in patients who developed anthracycline-related congestive heart failure after childhood cancer . Cancer112 , 2789 – 2795 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Blanco JG , SunCL , LandierWet al. Anthracycline-related cardiomyopathy after childhood cancer: role of polymorphisms in carbonyl reductase genes – a report from the Children’s Oncology Group . J. Clin. Oncol.30 , 1415 – 1421 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Lubieniecka JM , LiuJ , HeffnerDet al. Single-nucleotide polymorphisms in aldo-keto and carbonyl reductase genes are not associated with acute cardiotoxicity after daunorubicin chemotherapy . Cancer Epidemiol. Biomarkers Prev.21 , 2118 – 2220 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Lubieniecka JM , GrahamJ , HeffnerDet al. A discovery study of daunorubicin induced cardiotoxicity in a sample of acute myeloid leukemia patients prioritizes P450 oxidoreductase polymorphisms as a potential risk factor . Front Genet.4 , 231 ( 2013 ).
   PubMedGoogle Scholar
• Krajinovic M . Further insight into the role of NQO1 in childhood leukemia . Haematologica90 , 1445 ( 2005 ).
   Google Scholar
• Barragan E , ColladoM , CerveraJet al. The GST deletions and NQO1*2 polymorphism confers interindividual variability of response to treatment in patients with acute myeloid leukemia . Leuk. Res.31 , 947 – 953 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Kim YK , KimHJ , MinWSet al. Prognostic significance of NQO1 polymorphism and GST-M1 deletion in de novo acute myeloid leukemia . Blood (ASH Annual Meeting Abstracts)112 , Abstract 4846 ( 2008 ).
   Google Scholar
• Naoe T , TagawaY , KiyoiHet al. Prognostic significance of the null genotype of glutathione S-transferase-T1 in patients with acute myeloid leukemia: increased early death after chemotherapy . Leukemia16 , 203 – 208 ( 2002 ).
   PubMed Web of Science ®Google Scholar
• Sofowora G , DishyV , XieHGet al. In-vivo effects of Glu298Asp endothelial nitric oxide synthase polymorphism . Pharmacogenetics11 , 809 – 814 ( 2011 ).
   Google Scholar
• Choi JY , BarlowWE , AlbainKSet al. Nitric oxide synthase variants and disease-free survival among treated and untreated breast cancer patients in a Southwest Oncology Group clinical trial . Clin. Cancer Res.15 , 5258 – 5266 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Siripin D , FucharoenS , TanyongDI . Nitric oxide and caspase 3 mediated cytokine induced apoptosis in acute leukemia . Asian Pac. J. Allergy Immunol.29 , 102 – 111 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• He H , XuYJ , YinJYet al. Association of nitric oxide synthase 3 (NOS3) 894 G>T polymorphism with prognostic outcomes of anthracycline in Chinese patients with acute myeloid leukemia . Clin. Exp. Pharmacol. Physiol.41 , 400 – 407 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Voso MT , D’Alo’F , GumieroDet al. The CYP1A1*2a allele is an independent prognostic factor for acute myeloid leukemia . Haematologica90 , 982 – 984 ( 2005 ).
   PubMed Web of Science ®Google Scholar
• Zhang J , YinL , LiangGet al. Detection of CYP2E1, a genetic biomarker of susceptibility to benzene metabolism toxicity in immortal human lymphocytes derived from the Han Chinese population . Biomed. Environ. Sci.24 , 300 – 309 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Birley AJ , JamesMR , DicksonPAet al. ADH single nucleotide polymorphism associations with alcohol metabolism in vivo . Hum. Mol. Genet.18 , 1533 – 1542 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• L’Ecuyer T , AllebbanZ , ThomasR , Vander HeideR . Glutathione S-transferase overexpression protects against anthracycline-induced H9C2 cell death . Am. J. Physiol. Heart Circ. Physiol.286 , H2057 – H2064 ( 2004 ).
   PubMed Web of Science ®Google Scholar
• Xiao Q , DengD , LiHet al. GSTT1 and GSTM1 polymorphisms predict treatment outcome for acute myeloid leukemia: a systematic review and meta-analysis . Ann. Hematol.93 , 1381 – 1390 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Emadi A , KarpJE . The clinically relevant pharmacogenomic changes in acute myelogenous leukemia . Pharmacogenomics13 , 1257 – 1269 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Voso MT , HohausS , GuidiFet al. Prognostic role of glutathione S-transferase polymorphisms in acute myeloid leukemia . Leukemia22 , 1685 – 1691 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Autrup JL , HoklandP , PedersenL , AutrupH . Effect of glutathione S-transferases on the survival of patients with acute myeloid leukaemia . Eur. J. Pharmacol.438 , 15 – 18 ( 2002 ).
   PubMed Web of Science ®Google Scholar
• Shi JY , RenZH , JiaoBet al. Genetic variations of DNA repair genes and their prognostic significance in patients with acute myeloid leukemia . Int. J. Cancer128 , 233 – 238 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Weiss JR , KopeckyKJ , GodwinJet al. Glutathione S-transferase (GSTM1, GSTT1 and GSTA1) polymorphisms and outcomes after treatment for acute myeloid leukemia: pharmacogenetics in Southwest Oncology Group (SWOG) clinical trials . Leukemia20 , 2169 – 2171 ( 2006 ).
   PubMed Web of Science ®Google Scholar
• Rossi D , RasiS , FranceschettiSet al. Analysis of the host pharmacogenetic background for prediction of outcome and toxicity in diffuse large B-cell lymphoma treated with R-CHOP21 . Leukemia23 , 1118 – 1126 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Sutton A , KhouryH , Prip-BuusCet al. The Ala16Val genetic dimorphism modulates the import of human manganese superoxide dismutase into rat liver mitochondria . Pharmacogenetics13 , 145 – 157 ( 2003 ).
   PubMedGoogle Scholar
• Koistinen P , RuuskaS , SailyMet al. An association between manganese superoxide dismutase polymorphism and outcome of chemotherapy in acute myeloid leukemia . Haematologica91 , 829 – 832 ( 2006 ).
   PubMed Web of Science ®Google Scholar
• Megías-Vericat JE , RojasL , HerreroMJet al. Positive impact of ABCB1 polymorphisms in overall survival and complete remission in acute myeloid leukemia: a systematic review and meta-analysis . Pharmacogenomics J.16 , 1 – 2 ( 2016 ).
   PubMed Web of Science ®Google Scholar
• Reichwagen A , ZiepertM , KreuzMet al. Association of NADPH oxidase polymorphisms with anthracycline-induced cardiotoxicity in the RICOVER-60 trial of patients with aggressive CD20(+) B-cell lymphoma . Pharmacogenomics16 , 361 – 372 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Gustafson HL , YaoS , GoldmanBHet al. Genetic polymorphisms in oxidative stress-related genes are associated with outcomes following treatment for aggressive B-cell non-Hodgkin lymphoma . Am. J. Hematol.89 , 639 – 645 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Sundaram M , YaoSY , IngramJCet al. Topology of a human equilibrative, nitrobenzylthioinosine (NBMPR)-sensitive nucleoside transporter (hENT1) implicated in the cellular uptake of adenosine and anti-cancer drugs . J. Biol. Chem.276 , 45270 – 45275 ( 2001 ).
   PubMed Web of Science ®Google Scholar
• Galmarini CM , ThomasX , CalvoFet al. In vivo mechanisms of resistance to cytarabine in acute myeloid leukaemia . Br. J. Haematol.117 , 860 – 868 ( 2002 ).
   PubMed Web of Science ®Google Scholar
• Osato DH , HuangCC , KawamotoMet al. Functional characterization in yeast of genetic variants in the human equilibrative nucleoside transporter, ENT1 . Pharmacogenetics13 , 297 – 301 ( 2003 ).
   PubMedGoogle Scholar
• Montero TD , RacordonD , BravoLet al. PPARα and PPARγ regulate the nucleoside transporter hENT1 . Biochem. Biophys. Res. Commun.419 , 405 – 411 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Kim KI , HuhIS , KimIWet al. Combined interaction of multi-locus genetic polymorphisms in cytarabine arabinoside metabolic pathway on clinical outcomes in adult acute myeloid leukaemia (AML) patients . Eur. J. Cancer49 , 403 – 410 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Wan H , ZhuJ , ChenFet al. SLC29A1 single nucleotide polymorphisms as independent prognostic predictors for survival of patients with acute myeloid leukemia: an in vitro study . J. Exp. Clin. Cancer Res.33 , 90 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Amaki J , OnizukaM , OhmachiKet al. Single nucleotide polymorphisms of cytarabine metabolic genes influence clinical outcome in acute myeloid leukemia patients receiving high-dose cytarabine therapy . Int. J. Hematol.101 , 543 – 553 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Seeringer A , Yi-JingH , SchlenkRet al. Pharmacogenetic factors in metabolism, transport and toxicity of cytarabine treatment in patients with AML . EJC Supplements7 , 572 – 573 ( 2009 ).
   Google Scholar
• Galmarini CM , ThomasX , CalvoFet al. Potential mechanisms of resistance to cytarabine in AML patients . Leuk. Res.26 , 621 – 629 ( 2002 ).
   PubMed Web of Science ®Google Scholar
• Shi JY , ShiZZ , ZhangSJ , ZhuYMet al. Association between single nucleotide polymorphisms in deoxycytidine kinase and treatment response among acute myeloid leukaemia patients . Pharmacogenetics14 , 759 – 768 ( 2004 ).
   PubMedGoogle Scholar
• Medina-Sanson A , Ramírez-PachecoA , Moreno-GuerreroSSet al. Role of genetic polymorphisms of deoxycytidine kinase and cytidine deaminase to predict risk of death in children with acute myeloid leukemia . Biomed. Res. Int.2015 , 309491 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Xu PP , ChenBA , FengJFet al. Association of polymorphisms of cytosine arabinoside-metabolizing enzyme gene with therapeutic efficacy for acute myeloid leukemia . Chin. Med. J. (Engl.)125 , 2137 – 2143 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Mahlknecht U , DransfeldCL , BulutNet al. SNP analyses in cytarabine metabolizing enzymes in AML patients and their impact on treatment response and patient survival: identification of CDA SNP C-451T as an independent prognostic parameter for survival . Leukemia23 , 1929 – 1932 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Falk IJ , FyrbergA , PaulEet al. Decreased survival in normal karyotype AML with single-nucleotide polymorphisms in genes encoding the AraC metabolizing enzymes cytidine deaminase and 5′-nucleotidase . Am. J. Hematol.88 , 1001 – 1006 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Lamba J , MitraA , CrewsKet al. Pathway based pharmacogenomics of cytarabine in pediatric acute myeloid leukemia . Blood (ASH Annual Meeting Abstracts)116 , Abstract 294 ( 2010 ).
   Google Scholar
• Yokoyama A , Okabe-KadoJ , WakimotoNet al. Evaluation by multivariate analysis of the diff erentiation inhibitory factor nm23 as a prognostic factor in acute myelogenous leukemia and application to other hematologic malignancies . Blood.91 , 1845 – 1851 ( 1998 ).
   PubMed Web of Science ®Google Scholar
• Braunagel D , SchaichM , KramerMet al. The T_T genotype within the NME1 promoter single nucleotide polymorphism -835 C/T is associated with an increased risk of cytarabine induced neurotoxicity in patients with acute myeloid leukemia . Leuk. Lymphoma53 , 952 – 957 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Dumontet C , BauchuEC , FabianowskaKet al. Common resistance mechanisms to nucleoside analogues in variants of the human erythroleukemic line K562 . Adv. Exp. Med. Biol.457 , 571 – 577 ( 1999 ).
   PubMed Web of Science ®Google Scholar
• Hunsucker SA , MitchellBS , SpychalaJ . The 5′-nucleotidases as regulators of nucleotide and drug metabolism . Pharmacol. Ther.107 , 1 – 30 ( 2005 ).
   PubMed Web of Science ®Google Scholar
• Galmarini CM , CrosE , ThomasXet al. The prognostic value of cN-II and cNIII enzymes in adult acute myeloid leukemia . Haematologica90 , 1699 – 1701 ( 2005 ).
   PubMed Web of Science ®Google Scholar
• Mitra AK , CrewsKR , PoundsSet al. Genetic variants in cytosolic 5′-nucleotidase II are associated with its expression and cytarabine sensitivity in HapMap cell lines and in patients with acute myeloid leukemia . J. Pharmacol. Exp. Ther.339 , 9 – 23 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Aksoy P , ZhuMJ , KalariKRet al. Cytosolic 5′-nucleotidase III (NT5C3): gene sequence variation and functional genomics . Pharmacogenet. Genomics.19 , 567 – 576 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Cheong HS , KohY , AhnKSet al. NT5C3 polymorphisms and outcome of first induction chemotherapy in acute myeloid leukemia . Pharmacogenet. Genomics.24 , 436 – 441 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Jahns-streubel G , ReuterC , Auf der LandwehrUet al. Activity of thymidine kinase and of polymerase alpha as well as activity and gene expression of deoxycytidine deaminase in leukemic blasts are correlated with clinical response in the setting of granulocyte-macrophage colony-stimulating factor based priming before and during TAD-9 induction therapy in acute myeloid leukemia . Blood90 , 1968 – 1976 ( 1998 ).
   Google Scholar
• Schröder JK , KirchC , SeeberS , SchutteJ . Structural and functional analysis of the cytidine deaminase gene in patients with acute myeloid leukaemia . Br. J. Haematol.103 , 1096 – 1103 ( 1998 ).
   PubMed Web of Science ®Google Scholar
• Gilbert JA , SalavaggioneOE , JiYet al. Gemcitabine pharmacogenomics: cytidine deaminase and deoxycytidylate deaminase gene resequencing and functional genomics . Clin. Cancer Res.12 , 1794 – 1803 ( 2006 ).
   PubMed Web of Science ®Google Scholar
• Yue L , SaikawaY , OtaKet al. A functional single-nucleotide polymorphism in the human cytidine deaminase gene contributing to ara-C sensitivity . Pharmacogenetics13 , 29 – 38 ( 2003 ).
   PubMedGoogle Scholar
• Abraham A , VaratharajanS , AbbasSet al. Cytidine deaminase genetic variants influence RNA expression and cytarabine cytotoxicity in acute myeloid leukemia . Pharmacogenomics13 , 269 – 282 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Fitzgerald SM , GoyalRK , OsborneWRet al. Identification of functional single nucleotide polymorphism haplotypes in the cytidine deaminase promoter . Hum. Genet.119 , 276 – 283 ( 2006 ).
   PubMed Web of Science ®Google Scholar
• Bhatla D , GerbingRB , AlonzoTAet al. Cytidine deaminase genotype and toxicity of cytosine arabinoside therapy in children with acute myeloid leukemia . Br. J. Haematol.144 , 388 – 394 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• He H , LiuZQ , LiXet al. The influence of cytidine deaminase -33delC polymorphism on treatment outcome with high-dose cytarabine in Chinese patients with relapsed acute myeloid leukaemia . J. Clin. Pharm. Ther. doi:10.1111/jcpt.12309 ( 2015 ) ( Epub ahead of print ).
   Web of Science ®Google Scholar
• Hyo Kim L , Sub CheongH , KohYet al. Cytidine deaminase polymorphisms and worse treatment response in normal karyotype AML . J. Hum. Genet.60 , 749 – 754 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Ciccolini J , DahanL , AndréNet al. Cytidine deaminase residual activity in serum is a predictive marker of early severe toxicities in adults after gemcitabine-based chemotherapies . J. Clin. Oncol.28 , 160 – 165 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Cao X , MitraAK , PoundsSet al. RRM1 and RRM2 pharmacogenetics: association with phenotypes in HapMap cell lines and acute myeloid leukemia patients . Pharmacogenomics14 , 1449 – 1466 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Allan JM , SmithAG , WheatleyKet al. Genetic variation in XPD predicts treatment outcome and risk of acute myeloid leukemia following chemotherapy . Blood104 , 3872 – 3877 ( 2004 ).
   PubMed Web of Science ®Google Scholar
• Mehta PA , AlonzoTA , GerbingRBet al. Children’s Oncology Group. XPD Lys751Gln polymorphism in the etiology and outcome of childhood acute myeloid leukemia: a Children’s Oncology Group report . Blood107 , 39 – 45 ( 2006 ).
   PubMed Web of Science ®Google Scholar
• Kuptsova N , KopeckyKJ , GodwinJet al. Polymorphisms in DNA repair genes and therapeutic outcomes of AML patients from SWOG clinical trials . Blood109 , 3936 – 3944 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Bhatla D , GerbingRB , AlonzoTAet al. Children’s Oncology Group. DNA repair polymorphisms and outcome of chemotherapy for acute myelogenous leukemia: a report from the Children’s Oncology Group . Leukemia22 , 265 – 272 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Strom SS , EsteyE , OutschoornUM , Garcia-ManeroG . Acute myeloid leukemia outcome: role of nucleotide excision repair polymorphisms in intermediate risk patients . Leuk. Lymphoma51 , 598 – 605 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• El-Tokhy MA , HusseinNA , BedewyAM , BarakatMR . XPD gene polymorphisms and the effects of induction chemotherapy in cytogenetically normal de novo acute myeloid leukemia patients . Hematology19 , 397 – 403 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Bănescu C , DuicuC , TrifaAP , DobreanuM . XRCC1 Arg194Trp and Arg399Gln polymorphisms are significantly associated with shorter survival in acute myeloid leukemia . Leuk. Lymphoma55 , 365 – 370 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Zeichner SB , AlghamdiS , ElhammadyG , PoppitiRJ . Prognostic significance of TP53 mutations and single nucleotide polymorphisms in acute myeloid leukemia: a case series and literature review . Asian Pac. J. Cancer Prev.15 , 1603 – 1609 ( 2015 ).
   Google Scholar
• Abdel Hamid TM , El GammalMM , EibeadGTet al. Clinical impact of SNP of P53 genes pathway on the adult AML patients . Hematology.20 , 328 – 335 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Falk IJ , WillanderK , ChairetiRet al. TP53 mutations and MDM2 (SNP309) identify subgroups of AML patients with impaired outcome . Eur. J. Haematol.94 , 355 – 362 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Takagi M , TsuchidaR , OguchiKet al. Identification and characterization of polymorphic variations of the ataxia telangiectasia mutated (ATM) gene in childhood Hodgkin disease . Blood103 , 283 – 290 ( 2004 ).
   PubMed Web of Science ®Google Scholar
• Leone G , FianchiL , PaganoL , VosoMT . Incidence and susceptibility to therapy-related myeloid neoplasms . Chem. Biol. Interact.184 , 39 – 45 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Penault-Llorca F , CayreA , Bouchet MishellanyFet al. Induction chemotherapy for breast carcinoma: predictive markers and relation with outcome . Int. J. Oncol.22 , 1319 – 1325 ( 2003 ).
   PubMed Web of Science ®Google Scholar
• Lightfoot TJ , JohnstonWT , PainterDet al. United Kingdom Childhood Cancer Study. Genetic variation in the folate metabolic pathway and risk of childhood leukemia . Blood115 , 3923 – 3929 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Sigglekow ND , PangonL , BrummerTet al. Mutated in colorectal cancer protein modulates the NFkB pathway . Anticancer Res.32 , 73 – 79 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Gamazon ER , LambaJK , PoundsSet al. Comprehensive genetic analysis of cytarabine sensitivity in a cell-based model identifies polymorphisms associated with outcome in AML patients . Blood121 , 4366 – 4376 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Kang H , WilsonCS , HarveyRCet al. Gene expression profiles predictive of outcome and age in infant acute lymphoblastic leukemia: a Children’s Oncology Group study . Blood119 , 1872 – 1881 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Ariyaratana S , LoebDM . The role of the Wilms tumour gene (WT1) in normal and malignant haematopoiesis . Expert Rev. Mol. Med.9 , 1 – 17 ( 2007 ).
   PubMedGoogle Scholar
• Megías-Vericat JE , HerreroMJ , RojasLet al. A systematic review and meta-analysis of the impact of WT1 polymorphism rs16754 in the effectiveness of standard chemotherapy in patients with acute myeloid leukemia . Pharmacogenomics J.16 , 30 – 40 ( 2016 ).
   PubMed Web of Science ®Google Scholar
• Wagner K , DammF , GohringGet al. Impact of IDH1 R132 mutations and an IDH1 single nucleotide polymorphism in cytogenetically normal acute myeloid leukemia: SNP rs11554137 is an adverse prognostic factor . J. Clin. Oncol.28 , 2356 – 2364 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Ho PA , KopeckyKJ , AlonzoTAet al. Prognostic implications of the IDH1 synonymous SNP rs11554137 in pediatric and adult AML: a report from the Children’s Oncology Group and SWOG . Blood118 , 4561 – 4566 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Willander K , FalkIJ , ChairetiRet al. Mutations in the isocitrate dehydrogenase 2 gene and IDH1 SNP 105C > T have a prognostic value in acute myeloid leukemia . Biomark. Res.2 , 18 ( 2014 ).
   PubMedGoogle Scholar
• Fasan A , HaferlachC , EderCet al. Evaluation of IDH1G105 polymorphism as prognostic marker in intermediate-risk AML . Ann. Hematol.94 , 1991 – 2001 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Wiseman DH , SmallHF , WilksDPet al. Elevated plasma 2-hydroxyglutarate in acute myeloid leukaemia: association with the IDH1 SNP rs11554137 and severe renal impairment . Br. J. Haematol.166 , 145 – 148 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Pérez-García A , De la CámaraR , Román-GómezJet al. GVHD/Immunotherapy Committee of the Spanish Group of Hematopoietic Stem Cell Transplantation. CTLA-4 polymorphisms and clinical outcome after allogeneic stem cell transplantation from HLA-identical sibling donors . Blood110 , 461 – 467 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Pérez-García A , BrunetS , BerlangaJJet al. CTLA-4 genotype and relapse incidence in patients with acute myeloid leukemia in first complete remission after induction chemotherapy . Leukemia23 , 486 – 491 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Zhao H , JiaM , WangZet al. Association between NOD2 single nucleotide polymorphisms and grade III–IV acute graft-versus-host disease: a meta-analysis . Hematology20 , 254 – 262 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Yomade O , Spies-WeisshartB , GlaserAet al. Impact of NOD2 polymorphisms on infectious complications following chemotherapy in patients with acute myeloid leukaemia . Ann. Hematol.92 , 1071 – 1077 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Mosrati MA , WillanderK , FalkIJet al. Association between TERT promoter polymorphisms and acute myeloid leukemia risk and prognosis . Oncotarget6 , 25109 – 25120 ( 2015 ).
   PubMedGoogle Scholar
• Kutny MA , AlonzoTA , GamazonERet al. Ethnic variation of TET2 SNP rs2454206 and association with clinical outcome in childhood AML: a report from the Children’s Oncology Group . Leukemia29 , 2424 – 2426 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Cingeetham A , VureeS , DunnaNRet al. Influence of BCL2-938C>A and BAX-248G>A promoter polymorphisms in the development of AML: case–control study from south India . Tumour Biol.36 , 7967 – 7976 ( 2015 ).
   PubMedGoogle Scholar
• Moon JH , SohnSK , LeeMHet al. BCL2 gene polymorphism could predict the treatment outcomes in acute myeloid leukemia patients . Leuk. Res.34 , 166 – 172 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Li L , FridleyB , KalariKet al. Gemcitabine and cytosine arabinoside cytotoxicity: association with lymphoblastoid cell expression . Cancer Res.68 , 7050 – 7058 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Li L , FridleyBL , KalariKet al. Gemcitabine and arabinosylcytosin pharmacogenomics: genome-wide association and drug response biomarkers . PLoS ONE4 , e7765 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Li L , FridleyBL , KalariKet al. Discovery of genetic biomarkers contributing to variation in drug response of cytidine analogues using human lymphoblastoid cell lines . BMC Genomics15 , 93 ( 2014 ).
   PubMed Web of Science ®Google Scholar